ImmunityBio analyst ratings
ImmunityBio analyst ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/03/2022 | 114.48% | Jefferies | → $8 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 08/03/2022 | 114.48% | 傑富瑞集團 | → 8 美元 | 啓動覆蓋範圍開啓 | → 購買 |
ImmunityBio Questions & Answers
ImmunityBio 問題與解答
The latest price target for ImmunityBio (NASDAQ: IBRX) was reported by Jefferies on August 3, 2022. The analyst firm set a price target for $8.00 expecting IBRX to rise to within 12 months (a possible 114.48% upside). 1 analyst firms have reported ratings in the last year.
傑富瑞集團於2022年8月3日公佈了ImmunityBio（納斯達克股票代碼：IBRX）的最新目標股價。該分析公司將目標股價定爲8.00美元，預計IBRX將在12個月內升至12個月內（可能上漲114.48％）。1家分析公司去年公佈了評級。
The latest analyst rating for ImmunityBio (NASDAQ: IBRX) was provided by Jefferies, and ImmunityBio initiated their buy rating.
傑富瑞集團提供了ImmunityBio（納斯達克股票代碼：IBRX）的最新分析師評級，ImmunityBio啓動了買入評級。
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ImmunityBio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ImmunityBio was filed on August 3, 2022 so you should expect the next rating to be made available sometime around August 3, 2023.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與ImmunityBio的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月做一次這樣的評級，因此每家公司每年應該獲得4次評級。ImmunityBio的最新評級是在2022年8月3日發佈的，因此您應該預計下一個評級將在2023年8月3日左右公佈。
While ratings are subjective and will change, the latest ImmunityBio (IBRX) rating was a initiated with a price target of $0.00 to $8.00. The current price ImmunityBio (IBRX) is trading at is $3.73, which is within the analyst's predicted range.
儘管評級是主觀的，並且會發生變化，但最新的ImmunityBio（IBRX）評級是啓動的，目標股價爲0.00美元至8.00美元。ImmunityBio（IBRX）目前的交易價格爲3.73美元，在分析師的預測區間內。